« Previous
Next »
Titles
- S12 nonclinical biodistribution considerations for gene therapy products: guidance for industry1
- S1B(R1) addendum to S1B testing for carcinogenicity of pharmaceuticals: guidance for industry1
- Safety considerations for container labels and carton labeling design to minimize medication errors1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : report to congressional addressees1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : testimony before the Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform, House of Representatives1
- Shared households as a safety net for older adults1
- Size, shape, and other physical attributes of generic tablets and capsules: guidance for industry1
- Smoking cessation and related indications: developing nicotine replacement therapy drug products : guidance for industry1
- Social Security's finances: testimony before the Subcommittee on Social Security, Committee on Ways and Means, U.S. House of Representatives1
- Social needs screening among non-federal acute care hospitals, 20221
- Soft (hydrophilic) daily wear contact lenses: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration staff1
- Solutions: state policies associated with higher participation1
- Some Medicare Advantage Organization denials of prior authorization requests raise concerns about beneficiary access to medically necessary care1
- Some skin substitute manufacturers did not comply with new ASP reporting requirements1
- Something needs to happen: what employees think employers should do about health care1
- Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- State Children's Health Insurance Program (SCHIP)2
- State all payer claims databases: identifying challenges and opportunities for conducting patient-centered outcomes research and multi-state studies1
- State biosimilar substitution laws could reduce consumer access and savings1